Airduo Respiclick (Fluticasone Propion/Salmeterol) Patent Expiration, LOE Window & CMS Spending

Airduo Respiclick (Fluticasone Propion/Salmeterol) by Teva Pharmaceuticals: FDA Orange Book LOE 2041-01-06, 5 AB generics, $1.8M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN208799 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-01-06
Orange Book Patents (*PED Extensions)14 patents (7 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$1.8M
2024 Medicare Part D Spend$257K
2024 Medicaid Spend$1.5M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 25.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.